THU071 Key Device Attributes For Injectable SRL Therapy In Acromegaly And NETs To Aid Clinical Decision Making
Authors: de Herder Wouter W , Melmed Shlomo , Follin Cecilia , Geilvoet Wanda , Jorgensen Jens Otto , Kolarova Teodora , Marks Muriël , Martin Wendy , Geerlings-Grootscholten Kim 
Published: October 2023

Disclosure: W.W. de Herder: Research Investigator; Self; Novartis Pharmaceuticals. Speaker; Self; Novartis Pharmaceuticals, Ipsen. S. Melmed: Consulting Fee; Self; Ionis Pharmaceuticals Inc., Ipsen, Novo Nordisk. Grant Recipient; Self; Pfizer Global R&D. C. Follin: None. W. Geilvoet: None. J.O. Jorgensen: Consulting Fee; Self; Novo Nordisk, Pfizer Global R&D. T. Kolarova: Grant Recipient; Self; Ipsen, ITM, AAA, Novartis Pharmaceuticals. M. Marks: None. W. Martin: Speaker; Self; Ipsen, AAA. K. Geerlings-Grootscholten: None.

Background: Adherence, effectiveness and safety of SRL injections are similar for self- vs healthcare setting administration but patient preferences and device satisfaction vary. Device ease of use is associated with more favourable outcomes for other injectable hormones. Aim: To define key injectable SRL device attributes associated with optimal injection experience by people living with NETs/acromegaly and HCPs, identifying differences at 95% confidence. Methods: The survey (Jun-Nov ‘22) included active current users (≥6 months) of an SRL device for NETs/acromegaly, and for HCPs currently treating patients with NETs/acromegaly. There were 263 respondents from Australia, Canada, Chile, Denmark, Ireland, Mexico, Norway, Spain, UK, and USA: 201 patients (P), 10 caregivers (C) and 52 HCPs. In the P/C group (n=211), 157 people lived with NET and 54 with acromegaly; 74% were female. The HCP group (n=52) comprised 29 physicians, 20 nurses and 3 others (research nurse, clinical manager, patient leader) treating acromegaly (n=22), NET (n=15), or both (n=15). Results: P/C treatment duration ranged from 0.5-&gt;15y (≥3y in 61%); 49% had experience with &gt;1 SRL device type. Most HCPs (62%) were prescribers, 48% administered SRL injections, 83% had experience with &gt;1 SRL device type. In the P/C group, NET patients were significantly more likely to have injections administered by an HCP in a hospital setting (54% vs 26% with acromegaly, p=0.05). Home administration was more common among acromegaly P/C (57%; 26% self-injected, 22% by caregiver, 9% by HCP) vs NET P/C (30%; 10%, 9% and 11%, respectively). Top 3 key device attributes preferred by the P/C group were: 1) confidence that the correct amount of drug is delivered (76%); 2) quick administration with minimal pain/discomfort (68%); 3) device safety (needle-safety system, low risk of contamination; 53%).The top 3 in the HCP group was: 1) quick administration with minimal pain/discomfort (69%); 2) correct use is easy to learn, confidence in handling the device (63%); 3) confidence that the correct amount of drug is delivered (62%). Ease of learning and confidence on correct use was significantly more likely to be selected as important by HCPs than P/C (63% vs 44%, p=0.05); ‘shorter/finer needles’ was significantly more likely to be selected by P/C than HCPs (48% vs 25%; p=0.05). ‘Easy to store and transport’ was significantly more likely to be selected by people living with acromegaly vs NET (59% vs 35%, p=0.05). Conclusions: Patient opinions are important to define key device attributes impacting the injection experience. Home administration is more common in acromegaly vs NET, as reflected in P/C device attribute preferences. Identified differences in key device attributes preferred by patients and HCPs inform the decision on which SRL device best fits individual patient needs. Developed with COR2ED, supported by an independent educational grant from Ipsen.

Presentation: Thursday, June 15, 2023